The drug glyburide for the treatment of type 2 diabetes (T2D) selectively inhibits NLRP3 inflammasomes, and the inhibition of NLRP3 by glyburide demonstrates for the first time that selective pharmacological inhibition is feasible (127). Here, NLRP3 is linked to type 2 diabetes mellitus.